ACLY and cancer: Mutant KRas upregulates de novo lipogenic genes, including FASN, ACC1, and ACLY, in lung cancer and gemcitabine-resistant pancreatic cancer cells [43,44], implying that KRAS-mutant cancer cells are more sensitive to inhibitors of FA synthesis.